Vaxart Past Earnings Performance
Past criteria checks 0/6
Vaxart's earnings have been declining at an average annual rate of -37.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 32.1% per year.
Key information
-37.1%
Earnings growth rate
30.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -32.1% |
| Return on equity | -142.7% |
| Net Margin | -1,117.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis
Sep 09Ray Stapleton joins Vaxart as CTO
Aug 31Vaxart shareholders approve proposal to increase number of shares
Aug 05Vaxart continues to lobby shareholders to vote to increase number of shares
Jul 29Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2
Jul 20Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success
Jul 07Vaxart: A Unique Vaccine Concern
Jun 14Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
Feb 26Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
Dec 09Vaxart: Differentiated Covid Oral Route Remains Viable
Nov 16Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program
Oct 30Vaxart: An Update
Oct 02Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth
Aug 25Vaxart: World's First Oral COVID Vaccine In Development
Jul 25FDA is set to decline new emergency use authorizations for COVID-19 vaccines
May 26We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely
May 11Enrollment underway in Vaxart's early-stage norovirus trial in elderly population
May 07Vaxart EPS misses by $0.04, misses on revenue
May 03Plucky Underdog Vaxart Still Banging Drum For Oral Vaccination
Apr 30Vaxart is soaring on more than 10 times the two-month average volume
Apr 27Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%
Mar 03Revenue & Expenses BreakdownBeta
How Vaxart makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -82 | 23 | 0 |
| 30 Sep 23 | 4 | -89 | 24 | 0 |
| 30 Jun 23 | 2 | -101 | 26 | 0 |
| 31 Mar 23 | 1 | -108 | 29 | 0 |
| 31 Dec 22 | 0 | -108 | 29 | 0 |
| 30 Sep 22 | 0 | -105 | 29 | 0 |
| 30 Jun 22 | 0 | -93 | 27 | 0 |
| 31 Mar 22 | 0 | -80 | 23 | 0 |
| 31 Dec 21 | 1 | -70 | 22 | 0 |
| 30 Sep 21 | 1 | -64 | 21 | 0 |
| 30 Jun 21 | 1 | -54 | 20 | 0 |
| 31 Mar 21 | 2 | -47 | 19 | 0 |
| 31 Dec 20 | 4 | -32 | 15 | 0 |
| 30 Sep 20 | 8 | -25 | 11 | 0 |
| 30 Jun 20 | 8 | -22 | 9 | 0 |
| 31 Mar 20 | 7 | -19 | 6 | 0 |
| 31 Dec 19 | 10 | -19 | 6 | 0 |
| 30 Sep 19 | 8 | -17 | 6 | 0 |
| 30 Jun 19 | 8 | -18 | 6 | 0 |
| 31 Mar 19 | 8 | -22 | 7 | 0 |
| 31 Dec 18 | 4 | -18 | 7 | 0 |
| 30 Sep 18 | 3 | -15 | 6 | 0 |
| 30 Jun 18 | 4 | -12 | 5 | 0 |
| 31 Mar 18 | 5 | -7 | 3 | 0 |
| 31 Dec 17 | 6 | -12 | 3 | 0 |
| 30 Sep 17 | 9 | -16 | 3 | 0 |
| 31 Dec 16 | 8 | -19 | 3 | 0 |
| 31 Dec 15 | 0 | -22 | 3 | 0 |
Quality Earnings: VXRT is currently unprofitable.
Growing Profit Margin: VXRT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VXRT is unprofitable, and losses have increased over the past 5 years at a rate of 37.1% per year.
Accelerating Growth: Unable to compare VXRT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VXRT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: VXRT has a negative Return on Equity (-142.66%), as it is currently unprofitable.